Development of the S-303 Pathogen Inactivation Technology for Red Blood Cell Concentrates
Open Access
- 1 January 2011
- journal article
- Published by S. Karger AG in Transfusion Medicine and Hemotherapy
- Vol. 38 (1) , 33-42
Abstract
Pathogen inactivation systems are in use in many European countries as routine procedures. However, a pathogen inactivation system for erythrocytes is currently not available. Although significant improvements have been made to decrease the incidence of transfusion-transmitted infections, risks remain for infectious disease agents specific to red blood cell concentrates, such as parasitic infections resulting in babesiosis and malaria. The pathogen inactivation system for erythrocytes utilizes S-303 and glutathione for the treatment of red blood cell concentrates. Preclinical studies to assess the pathogen inactivation efficacy and toxicology as well as preliminary clinical studies have been completed. Preclinical studies have shown log reduction for leukocytes, several viruses and bacteria in excess of 4 to 6 logs. Preclinical toxicology studies were conducted to enable the initiation of two phase III clinical studies in the USA for support of acute and chronic anemia. A second-generation system was developed after observation of an unexpected immune response in two chronic anemia patients. Preclinical pathogen inactivation studies, serological evaluations and a clinical study to evaluate survival of S-303-treated erythrocytes have been completed to support advanced development of the S-303 pathogen inactivation system. A functional system for the inactivation of red blood cell concentrates has been completed and is reaching clinical application.Keywords
This publication has 34 references indexed in Scilit:
- Transfusion‐associated infections: 50 years of relentless challenges and remarkable progressTransfusion, 2010
- Pathogen Reduction: A Precautionary Principle ParadigmTransfusion Medicine Reviews, 2008
- Pathogen inactivation: making decisions about new technologiesTransfusion, 2007
- A randomized, controlled Phase III trial of therapeutic plasma exchange with fresh‐frozen plasma (FFP) prepared with amotosalen and ultraviolet A light compared to untreated FFP in thrombotic thrombocytopenic purpuraTransfusion, 2006
- Photochemical treatment of plasma with amotosalen and long‐wavelength ultraviolet light inactivates pathogens while retaining coagulation functionTransfusion, 2006
- Photochemically treated fresh frozen plasma for transfusion of patients with acquired coagulopathy of liver diseaseBlood, 2006
- Therapeutic efficacy and safety of photochemically treated apheresis platelets processed with an optimized integrated setTransfusion, 2005
- Photochemical treatment of platelet concentrates with amotosalen and long‐wavelength ultraviolet light inactivates a broad spectrum of pathogenic bacteriaTransfusion, 2004
- Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT TrialBlood, 2004
- Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trialBlood, 2002